FDA guidance changes affect biosimilar approval, impacting Coherus Oncology, Inc.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA guidance changes affect biosimilar approval, impacting Coherus Oncology, Inc.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Experimental therapies require approval from the FDA.
- FDA rule changes are causing delays in product approval, leading to the process exceeding Congressional mandated timeframes.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- The FDA has issued a Major Amendment regarding AxoGen's submission on August 25, 2025.